Clinical Trial

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase 1b/II, open-label study to evaluate the safety, tolerability, pharmacokinetics and antitumor activities of D-1553 in combination with IN10018 in subjects with locally advanced or metastatic solid tumor with KRAS G12C mutation.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-12-04; most recent amendment 2026-06-30.
Status change: Recruiting → Active, Not Recruiting 2026-03-21
Status change: Enrolling by Invitation → Recruiting 2024-01-17
Trial Details
NCT Number NCT06166836
Lead Sponsor InxMed (Shanghai) Co., Ltd.
Collaborators: InventisBio Co., Ltd
Conditions Solid Tumor
Enrollment 140 participants
Start Date 2022-10-12
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-02